Member Info for MisterPositive

Why is this board hijacked by just a few people ??

This is a public board to have discussion about the company and your investment. Different people will interpret things differently.

Firstly - people should only use RNS and official Company presentations & interviews etc to base any investment decisions. Also do your own research.

Secondly - any issues / grievance anybody has against someone, simply filter them OR report them to LSE admin with your reasons. Let the authorities take appropriate action.

No need to CLUTTER this board please.

So difficult to read any decent posts without having to sift through a barrage of unnecessary posts.

MP

Concensus Analyst price target is 6.22 - 6.40 pence near term. Higher revisions expected based on newsflow in 2026.

People just need to call it TRUCE and put their differences aside. There is NO Gold medal here for the winner.

We are on the cusp of "Major re-rate" here after having consolidated nicely for long time.

With RNS expected any day now, expect this to shoot up towards 2p - 2.50p in coming days.

Next 3-6 months go see a whole new re-rate upwards. Negative & toxic comments aimed at fellow posters will put off any potential investors looking in and Delay proper share price re-rate.

Not been upto date, but does anybody here know how much cash $$$ Petrochina owes MATD for the oil sales ?

SmartInvestor1

Renewables numbers are very compelling.

I also prefer Monday RNS...sets positive tone for rest of the week.

Nice juicy Monday RNS... expect re-test of 1.60 p

Looks very OVERSOLD. Bounce is expected

Yes Hamm...same one.

MATD is "Finally now" in much better shape after bit of business restructuring over past years. I look forward to 2026 with great optimism.

I am quite happy with the "Renewable" business arm of MATD which is high margin and very profitable business.

PetroMatad now emerging as more "Diversified" business conglomerate that will soon start firing on ALL CYLINDERS like V12-Turbo.

Great news for SunSteppe Renewable Energy (SRE).

MOU with OT (Rio Tinto) for renewable energy is a fabulous start for SunSteppe.

Would expect Sunsteppe Order book to grow strongly from here onwards after onboarding Blue chip customer like RIO TINTO.

1p should be taken out very soon.

Would expect a re-test of 1.60 (Oct) followed by re-test of 2.50 in May this year in quick order.

Triggers will be Newsflow updates on many fronts. This could jump to +10p in Q1 as early as Jan 2026 in my view looking at previous patterns for MATD.

My prediction for Q2 (Apr - June) is 15 - 20p

Could go even higher depending on Newsflow from Heron 1-2 and Gazelle and the upcoming FarmOut deal terms.

"There are over 523 million people worldwide with some form of cardiovascular disease (CVD) as of 2019, and this number continues to rise. The World Heart Federation reported that over 640 million people are affected by cardiovascular disease."

At $500 per test...use your imagination to work out the numbers.

"The AHA reports that approximately 82.6 million people in the United States currently have one or more forms of cardiovascular disease (CVD), making it a leading cause of death for both men and women".

That number is rising with 2050 figure estimated to reach 184 million adults.

With what Genincode has developed, this company is going to be Bought Out sooner or later at "many Multiples" of current low £10m MCap with BIG PHARMA bidding war down the road. IMHO

"The CARDIO inCode-Score® test recently received New York State licensure to complete its US Centers for Medicare and Medicaid Services (CMS) state coverage with the test included in the 2025 Clinical Laboratory Fee Schedule at an average reimbursement of ~$500.00 per test."

Estimated 1.2 million adults listed in New York state alone with cardio vascular disease (CVD).

At $500 per test = $600 million potential revenues

Big Buy order most likely filled by now.

MMs had to collect shares from weak hands.

Should have got enough now for afternoon session and US open.

Thermo Fisher collaboration news should make newswire in US also as they just waking up.

£100m MCap here = 36p

"The partnership will use Thermo Fisher’s QuantStudio™ 5 Dx Real-Time PCR System and is aimed at tapping into the sizeable cardiovascular devices markets, worth about US$22.8 billion in the US and €12.5 billion in Europe."

"CARDIO inCode-Score® already holds New York State licensure and is set to appear on the 2025 Clinical Laboratory Fee Schedule with an average reimbursement of around $500 per test."

Agree. GENI is far more advanced compared to e.g. IMM that went from 1.5p to 19.40p in 4 weeks.

GENI now with Thermo Fisher deal could do lot more than what IMM did between Aug & Sep 2025.

GENI could hit £100m MCap in quick order. Lookout for any Holding RNS in coming days/weeks as SmallCap fund Managers also pile in here.

Would expect both US and UK SmallCap fund Managers to be all over this now...may be they

Best performer in 2026.

Wow...their annual revenue is $42 billion

Thermo Fisher can just gobble up GENI for lets say only $500m - $600m down the road or in 2026 after FDA...

That would be around £1.50 - £1.80/ share

Current MCap c £10m ??

Numbers are just staggering.

Added more above 4p today. Amazing news.

This can easily DOUBLE in next few sessions. May be 10p+ in coming days. Re-rate has started.

Agree - FDA should be a done deal in my opinion. Clue was in yesterday's RNS after Approval from NEW YORK state.

Amazing RNS back to back after NEW YORK state approval yesterday.

"An estimated 1.2 million adults in New York State reported having cardiovascular disease (CVD) in 2021, based on a 7.8% prevalence rate. This number is higher for adults aged 65 and older, with 17.7% reporting some form of CVD in 2021."

1.2 million adults is just NEW YORK state.

At $500 revenue per test...you do the maths...

Agree. This is SIGNIFICANTLY UNDERVALUED.

$500 per test in New York state alone.

For 100,000 patients = $50 million

Current MCap £8m ??

Let the numbers sink in for Market to wake up.

Expect a Major re-rate in coming days/weeks.